Mark A. Demitrack, MD

Original Research

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period

September 16, 2014

David L. Dunner, Scott T. Aaronson, Harold A. Sackeim, et al

Original Research

Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial

March 14, 2008

David H. Avery, Keith E. Isenberg, Shirlene M. Sampson, et al

Original Research

Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience From Acute Exposure, Extended Exposure, and During Reintroduction Treatment

February 14, 2008

Philip G. Janicak, Shirlene M. Sampson, Mustafa M. Husain, et al

Academic Highlights

Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression.

February 15, 2007

Alan F. Schatzberg, Mark A. Demitrack, John P. O' Reardon, et al

Original Research

Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial

April 1, 2002

Michael J. Detke, Yili Lu, David J. Goldstein, et al

Original Research

Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial

March 1, 2002

David J. Goldstein, Craig Mallinckrodt, Yili Lu, et al

Article

Can Monoamine-Based Therapies Be Improved?

February 1, 2002

Mark A. Demitrack

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period

Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial

Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience From Acute Exposure, Extended Exposure, and During Reintroduction Treatment

Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression.

Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial

Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial

Can Monoamine-Based Therapies Be Improved?

ELSEWHERE:

FOLLOW US:

Mark A. Demitrack, MD

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period

Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial

Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience From Acute Exposure, Extended Exposure, and During Reintroduction Treatment

Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression.

Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial

Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial

Can Monoamine-Based Therapies Be Improved?

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles